Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2005

Conditions
Healthy
Interventions
DRUG

BILR 355 BS /1B, current low dose formulation

DRUG

BILR 355 BS /1B, current high dose formulation

DRUG

BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation

DRUG

BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation

DRUG

BILR 355 BS - Suspension low dose

DRUG

BILR 355 BS - Suspension high dose

DRUG

Ritonavir

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02259868 - Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects | Biotech Hunter | Biotech Hunter